NuVasive announced that it received 510(k) clearance from the U.S. FDA for the use of its Precice all-internal limb lengthening solution to include pediatric patients. The expanded clearance extends the clinical benefits of Precice to a wider range of patients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NUVA:
- NuVasive Announces Fourth Quarter and Full-Year 2022 Financial Results and 2023 Net Sales Guidance
- NuVasive reports Q4 non-GAAP EPS 43c, consensus 51c
- Globus Medical price target lowered to $75 from $82 at Barclays
- Globus Medical downgraded to Underperform from Buy at BofA
- Globus Medical downgraded to Equal Weight from Overweight at Wells Fargo